Cortexyme Announces Publication of New Data Further Demonstrating the Therapeutic Potential of COR388, the Company?s Lead Investigational Medicine

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat Alzheimer?s and other degenerative diseases, today announced the publication of new data in Pharmacology Research and Perspectives revealing further detail about the pharmacodynamics and utility of the company?s lead investigational medicine, COR388. The data provides additional evidence on the ability of COR3

Click to view original post